Skip to content

Phase III trial of articaine hydrochloride with adrenaline bitartrate

Phase III trial of articaine hydrochloride with adrenaline bitartrate to compare to lidocaine hydrochloride with adrenaline bitartrate in dental patients -Multicenter, randomized, single-blind, Non-inferiority study-

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2061210012
Enrollment
86
Registered
2021-06-15
Start date
2021-07-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental patients

Interventions

Either articaine hydrochloride and adrenaline bitartrate (3.4 - 5.1 mL) or lidocaine hydrochloride and adrenaline bitartrate (3.6 - 5.4 mL) is injected in the oral cavity.

Sponsors

Miyawaki Takuya
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who are scheduled to undergo extraction of a mandibular wisdom tooth(a half-impacted tooth).

Exclusion criteria

Exclusion criteria: 1) Extraction of complete impacted wisdom tooth or maxillofacial surgery 2) Patients with the history of allergy to the composition of this investigational new drug, amide type local anesthetic, adrenaline bitartrate or sodium metabisulfite 3) Patients with hypertension whose systolic blood pressure or diastolic blood pressure is over 180 mmHg or 110 mmHg, respectively. 4) Patients with symptom of arteriosclerosis or patients with unstable coronary artery disease. 5) Patients with cardiac failure whose Metabolic Equivalents (MET) are under 4 6) Hyperthyroidism patients with the symptom of it 7) Patients with uncontrolled diabetes mellitus 8) Patients with severe medical diseases (hepatic disorder, renal disorder, cardiovascular diseases, endocrine system diseases, respiratory diseases etc.) or patients with severe psychiatric diseases. 9) Patients in pregnancy or the possibility of pregnancy. Breast-feeding patients. 10) Patients who received another investigational new drug within 12 weeks before this investigational new drug 11) Patients who had received or is receiving medicines or treatments which influence to the pain evaluation within 1 week before screening . 12) Patients with HIV antibody positivity, HBs antigen positivity or HCV antibody positivity. 13) Patients who are determined as inadequacy by the principal investigator or subinvestigater.

Design outcomes

Primary

MeasureTime frame
VAS (visual analog scale) during dental procedures after the investigational new drug injection (evaluated by patients)

Contacts

Public ContactMakoto Iwane

Okayama University Hospital

makoto-iwane@okayama-u.ac.jp+81-86-235-7515

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026